Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Table 3 Features of pazopanib-induced hypertension in the 20 patients in which it developed

Parameter	Value	Range
Change in systolic BP (mm Hg)	8.2 [−3.7-18.4]	−54.6-26.3
Change in diastolic BP (mm Hg)	5.6 [0.4-11.4]	−8.3-18.2
Maximal systolic BP (mm Hg)	167.5 [159.5-186.5]	148-195
Maximal diastolic BP (mm Hg)	96 [92-106.5]	80-112
Time until pazopanib-induced HTN (days)	24.5 [14.5-53.5]	7-641
Antihypertensive dose increased or new agent added	17 (85)
No preexisting HTN	6 (30)
Class of antihypertensive started or intensified
ACEIs or ARBs	12 (46)
Beta-blockers	3 (12)
Calcium channel blockers	7 (27)
Diuretics	1 (4)
Others*	3 (12)

BP blood pressure, HTN hypertension, n number, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker
Data presented as a number with percent (%) or median [1st quartile-3rd quartile]
^*Clonidine (n = 2) and hydralazine (n = 1)

ISSN: 2057-3804